Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018. View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-11

AUTHORS

Yara-Natalie Abo, Erika Refsum, Nicola Mackie, Hermione Lyall, Gareth Tudor-Williams, Caroline Foster

ABSTRACT

BACKGROUND AND OBJECTIVE: Integrase strand transfer inhibitors (INSTIs) have become the preferred first-line antiretroviral therapy in adults. There is paucity of published data on their use in children outside of clinical trials, particularly long-term safety and tolerability. This study aimed to describe INSTI use including the number of, and reasons for INSTI discontinuation. METHODS: We conducted a retrospective cohort analysis by database and electronic record review of children aged under 18 years with perinatally acquired human immunodeficiency virus who started INSTI-based antiretroviral therapy between May 2009 and March 2018, in a single tertiary centre. RESULTS: Fifty-six INSTI-based regimens were prescribed in 54 children, 64.9% from 2015 onwards. Twenty-one of 56 (37.5%) regimens commenced with raltegravir, 29 (51.8%) with dolutegravir and six (10.7%) with elvitegravir. The median age at the start of treatment was 15 years (interquartile range 13.5-16.4) with a median duration of INSTI-antiretroviral therapy of 1.65 years (range 0.01-8.8). Twenty-four children had a detectable viral load at the start INSTI therapy; 20 (83%) achieving viral suppression in a median of 26 days (interquartile range 19.5-34.5). There were 26 discontinuations of INSTI-based antiretroviral therapy after a median of 183 days; 9/26 because of adverse events. Four of nine adverse events were attributed to INSTI use, all in patients taking dolutegravir and the adverse events were neuropsychiatric and gastrointestinal in nature. CONCLUSIONS: INSTI-based regimens were generally efficacious and well tolerated in this paediatric cohort, with 4/26 discontinuations due to INSTI-attributed adverse events. Further post-marketing surveillance of INSTI use in children is warranted. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-019-00783-8

DOI

http://dx.doi.org/10.1007/s40261-019-00783-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113378594

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30976998


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "St Mary's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.426467.5", 
          "name": [
            "Imperial College Healthcare NHS Trust, London, UK. Yara.a1@gmail.com.", 
            "St Mary's Hospital, Praed Street, London, W2 1NY, UK. Yara.a1@gmail.com."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abo", 
        "givenName": "Yara-Natalie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College London", 
          "id": "https://www.grid.ac/institutes/grid.7445.2", 
          "name": [
            "Imperial College London, London, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Refsum", 
        "givenName": "Erika", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College Healthcare NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.417895.6", 
          "name": [
            "Imperial College Healthcare NHS Trust, London, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mackie", 
        "givenName": "Nicola", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College Healthcare NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.417895.6", 
          "name": [
            "Imperial College Healthcare NHS Trust, London, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lyall", 
        "givenName": "Hermione", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College London", 
          "id": "https://www.grid.ac/institutes/grid.7445.2", 
          "name": [
            "Imperial College London, London, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tudor-Williams", 
        "givenName": "Gareth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College Healthcare NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.417895.6", 
          "name": [
            "Imperial College Healthcare NHS Trust, London, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Foster", 
        "givenName": "Caroline", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1371/journal.pone.0052562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004120229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dks416", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017828499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/archdischild-2014-307019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023186632"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/inf.0000000000000848", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029046849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/inf.0000000000000848", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029046849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1506816", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030826445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1468-1293.2008.00654.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040026998"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/hiv.12468", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046733696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cid/cit696", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046768445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40121-014-0024-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047949701", 
          "https://doi.org/10.1007/s40121-014-0024-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0000000000001279", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051201610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/qad.0000000000001279", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051201610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkw464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059736558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jpids/piu146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059826272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkx053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083932514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7448/ias.20.4.21520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085537033"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-11", 
    "datePublishedReg": "2019-04-11", 
    "description": "BACKGROUND AND OBJECTIVE: Integrase strand transfer inhibitors (INSTIs) have become the preferred first-line antiretroviral therapy in adults. There is paucity of published data on their use in children outside of clinical trials, particularly long-term safety and tolerability. This study aimed to describe INSTI use including the number of, and reasons for INSTI discontinuation.\nMETHODS: We conducted a retrospective cohort analysis by database and electronic record review of children aged under 18\u00a0years with perinatally acquired human immunodeficiency virus who started INSTI-based antiretroviral therapy between May 2009 and March 2018, in a single tertiary centre.\nRESULTS: Fifty-six INSTI-based regimens were prescribed in 54 children, 64.9% from 2015 onwards. Twenty-one of 56 (37.5%) regimens commenced with raltegravir, 29 (51.8%) with dolutegravir and six (10.7%) with elvitegravir. The median age at the start of treatment was 15\u00a0years (interquartile range 13.5-16.4) with a median duration of INSTI-antiretroviral therapy of 1.65\u00a0years (range 0.01-8.8). Twenty-four children had a detectable viral load at the start INSTI therapy; 20 (83%) achieving viral suppression in a median of 26\u00a0days (interquartile range 19.5-34.5). There were 26 discontinuations of INSTI-based antiretroviral therapy after a median of 183\u00a0days; 9/26 because of adverse events. Four of nine adverse events were attributed to INSTI use, all in patients taking dolutegravir and the adverse events were neuropsychiatric and gastrointestinal in nature.\nCONCLUSIONS: INSTI-based regimens were generally efficacious and well tolerated in this paediatric cohort, with 4/26 discontinuations due to INSTI-attributed adverse events. Further post-marketing surveillance of INSTI use in children is warranted.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40261-019-00783-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "type": "Periodical"
      }
    ], 
    "name": "Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-019-00783-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113378594"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9504817"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30976998"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-019-00783-8", 
      "https://app.dimensions.ai/details/publication/pub.1113378594"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106816_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s40261-019-00783-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00783-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00783-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00783-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-019-00783-8'


 

This table displays all metadata directly associated to this object as RDF triples.

137 TRIPLES      20 PREDICATES      38 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-019-00783-8 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4c9ab60e9d91454fb383d5d6dfd0fcc9
4 schema:citation sg:pub.10.1007/s40121-014-0024-z
5 https://doi.org/10.1056/nejmoa1506816
6 https://doi.org/10.1093/cid/cit696
7 https://doi.org/10.1093/jac/dks416
8 https://doi.org/10.1093/jac/dkw464
9 https://doi.org/10.1093/jac/dkx053
10 https://doi.org/10.1093/jpids/piu146
11 https://doi.org/10.1097/inf.0000000000000848
12 https://doi.org/10.1097/qad.0000000000001279
13 https://doi.org/10.1111/hiv.12468
14 https://doi.org/10.1111/j.1468-1293.2008.00654.x
15 https://doi.org/10.1136/archdischild-2014-307019
16 https://doi.org/10.1371/journal.pone.0052562
17 https://doi.org/10.7448/ias.20.4.21520
18 schema:datePublished 2019-04-11
19 schema:datePublishedReg 2019-04-11
20 schema:description BACKGROUND AND OBJECTIVE: Integrase strand transfer inhibitors (INSTIs) have become the preferred first-line antiretroviral therapy in adults. There is paucity of published data on their use in children outside of clinical trials, particularly long-term safety and tolerability. This study aimed to describe INSTI use including the number of, and reasons for INSTI discontinuation. METHODS: We conducted a retrospective cohort analysis by database and electronic record review of children aged under 18 years with perinatally acquired human immunodeficiency virus who started INSTI-based antiretroviral therapy between May 2009 and March 2018, in a single tertiary centre. RESULTS: Fifty-six INSTI-based regimens were prescribed in 54 children, 64.9% from 2015 onwards. Twenty-one of 56 (37.5%) regimens commenced with raltegravir, 29 (51.8%) with dolutegravir and six (10.7%) with elvitegravir. The median age at the start of treatment was 15 years (interquartile range 13.5-16.4) with a median duration of INSTI-antiretroviral therapy of 1.65 years (range 0.01-8.8). Twenty-four children had a detectable viral load at the start INSTI therapy; 20 (83%) achieving viral suppression in a median of 26 days (interquartile range 19.5-34.5). There were 26 discontinuations of INSTI-based antiretroviral therapy after a median of 183 days; 9/26 because of adverse events. Four of nine adverse events were attributed to INSTI use, all in patients taking dolutegravir and the adverse events were neuropsychiatric and gastrointestinal in nature. CONCLUSIONS: INSTI-based regimens were generally efficacious and well tolerated in this paediatric cohort, with 4/26 discontinuations due to INSTI-attributed adverse events. Further post-marketing surveillance of INSTI use in children is warranted.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf sg:journal.1100199
25 schema:name Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
26 schema:productId N51f2bb6c53c042389be658eb8c8d23fd
27 N6b10cc332a4244dba030d408c91adc0b
28 N7e4ec4939c40437dab9f6f8b1fb0efa9
29 Nc95ddc5a238141c2991701534d611320
30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113378594
31 https://doi.org/10.1007/s40261-019-00783-8
32 schema:sdDatePublished 2019-04-16T06:22
33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
34 schema:sdPublisher N432e44d5dcf8427da80d08614d8b8814
35 schema:url http://link.springer.com/10.1007/s40261-019-00783-8
36 sgo:license sg:explorer/license/
37 sgo:sdDataset articles
38 rdf:type schema:ScholarlyArticle
39 N1d358742f4ab48758e334268b2d963f4 schema:affiliation https://www.grid.ac/institutes/grid.417895.6
40 schema:familyName Foster
41 schema:givenName Caroline
42 rdf:type schema:Person
43 N2c3e0b1ee3ba44c7943894b7b5f6e2d6 schema:affiliation https://www.grid.ac/institutes/grid.7445.2
44 schema:familyName Tudor-Williams
45 schema:givenName Gareth
46 rdf:type schema:Person
47 N432e44d5dcf8427da80d08614d8b8814 schema:name Springer Nature - SN SciGraph project
48 rdf:type schema:Organization
49 N4c9ab60e9d91454fb383d5d6dfd0fcc9 rdf:first N915edda38bd546d2bf0db39c4abf7439
50 rdf:rest N7e10063c24b24501b0dfa039b3a6fc13
51 N51f2bb6c53c042389be658eb8c8d23fd schema:name dimensions_id
52 schema:value pub.1113378594
53 rdf:type schema:PropertyValue
54 N6b10cc332a4244dba030d408c91adc0b schema:name doi
55 schema:value 10.1007/s40261-019-00783-8
56 rdf:type schema:PropertyValue
57 N6d9c2a083a8b489f8ba4fd78a1f64ac4 schema:affiliation https://www.grid.ac/institutes/grid.417895.6
58 schema:familyName Lyall
59 schema:givenName Hermione
60 rdf:type schema:Person
61 N7e10063c24b24501b0dfa039b3a6fc13 rdf:first N9cb51430bec64d8cb09ab6d75bcc382b
62 rdf:rest Nb3ccddee014f4c4aaae49fe482724f8c
63 N7e4ec4939c40437dab9f6f8b1fb0efa9 schema:name pubmed_id
64 schema:value 30976998
65 rdf:type schema:PropertyValue
66 N7f38b65f4851473eab805956622bf013 schema:affiliation https://www.grid.ac/institutes/grid.417895.6
67 schema:familyName Mackie
68 schema:givenName Nicola
69 rdf:type schema:Person
70 N915edda38bd546d2bf0db39c4abf7439 schema:affiliation https://www.grid.ac/institutes/grid.426467.5
71 schema:familyName Abo
72 schema:givenName Yara-Natalie
73 rdf:type schema:Person
74 N9cb51430bec64d8cb09ab6d75bcc382b schema:affiliation https://www.grid.ac/institutes/grid.7445.2
75 schema:familyName Refsum
76 schema:givenName Erika
77 rdf:type schema:Person
78 Nae36ae125c864440b38cff58134cf174 rdf:first N2c3e0b1ee3ba44c7943894b7b5f6e2d6
79 rdf:rest Neb62e63f1b9b4e5897702de01dbe7391
80 Nb3ccddee014f4c4aaae49fe482724f8c rdf:first N7f38b65f4851473eab805956622bf013
81 rdf:rest Nb4bbf97974a84cbda5e4c9d31de2c981
82 Nb4bbf97974a84cbda5e4c9d31de2c981 rdf:first N6d9c2a083a8b489f8ba4fd78a1f64ac4
83 rdf:rest Nae36ae125c864440b38cff58134cf174
84 Nc95ddc5a238141c2991701534d611320 schema:name nlm_unique_id
85 schema:value 9504817
86 rdf:type schema:PropertyValue
87 Neb62e63f1b9b4e5897702de01dbe7391 rdf:first N1d358742f4ab48758e334268b2d963f4
88 rdf:rest rdf:nil
89 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
90 schema:name Medical and Health Sciences
91 rdf:type schema:DefinedTerm
92 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
93 schema:name Clinical Sciences
94 rdf:type schema:DefinedTerm
95 sg:journal.1100199 schema:issn 1173-2563
96 1179-1918
97 schema:name Clinical Drug Investigation
98 rdf:type schema:Periodical
99 sg:pub.10.1007/s40121-014-0024-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1047949701
100 https://doi.org/10.1007/s40121-014-0024-z
101 rdf:type schema:CreativeWork
102 https://doi.org/10.1056/nejmoa1506816 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030826445
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1093/cid/cit696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046768445
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1093/jac/dks416 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017828499
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1093/jac/dkw464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059736558
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1093/jac/dkx053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083932514
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1093/jpids/piu146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059826272
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1097/inf.0000000000000848 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029046849
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1097/qad.0000000000001279 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051201610
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1111/hiv.12468 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046733696
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1111/j.1468-1293.2008.00654.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1040026998
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1136/archdischild-2014-307019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023186632
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1371/journal.pone.0052562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004120229
125 rdf:type schema:CreativeWork
126 https://doi.org/10.7448/ias.20.4.21520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085537033
127 rdf:type schema:CreativeWork
128 https://www.grid.ac/institutes/grid.417895.6 schema:alternateName Imperial College Healthcare NHS Trust
129 schema:name Imperial College Healthcare NHS Trust, London, UK.
130 rdf:type schema:Organization
131 https://www.grid.ac/institutes/grid.426467.5 schema:alternateName St Mary's Hospital
132 schema:name Imperial College Healthcare NHS Trust, London, UK. Yara.a1@gmail.com.
133 St Mary's Hospital, Praed Street, London, W2 1NY, UK. Yara.a1@gmail.com.
134 rdf:type schema:Organization
135 https://www.grid.ac/institutes/grid.7445.2 schema:alternateName Imperial College London
136 schema:name Imperial College London, London, UK.
137 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...